ATIR-101

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameATIR-101
Drug Alias NameATIR-101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsGraft vs Host DiseaseMyeloproliferative DisordersMyelodysplastic Syndromes +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[13] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesKiadis Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKiadis Pharma
Active IndicationsN/A
Inactive IndicationsGraft vs Host DiseaseMyeloproliferative DisordersMyelodysplastic Syndromes +[11] 

Other Information

ATC CodeN/A
Related LinksN/A